FDA Approves EluNIR Drug-Eluting Stent System

Cordis, Cardinal Health’s interventional cardiovascular business, and Medinol have scored FDA approval for their EluNIR drug-eluting stent system.

The EluNIR DES, which previously obtained CE Marking, is indicated for treating narrowing or blockages in patients with coronary artery disease — a common type of cardiovascular disease.

The stent was designed to have the "narrowest strut width of any stent in the U.S. market" to make it easy to use for clinicians, the companies said.